Moleculin Biotech

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MBRX and other ETFs, options, and stocks.

About MBRX

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. 

CEO
Walter V. Klemp
CEOWalter V. Klemp
Employees
17
Employees17
Headquarters
Houston, Texas
HeadquartersHouston, Texas
Founded
2015
Founded2015
Employees
17
Employees17

MBRX Key Statistics

Market cap
12.59M
Market cap12.59M
Price-Earnings ratio
-0.07
Price-Earnings ratio-0.07
Dividend yield
Dividend yield
Average volume
290.27K
Average volume290.27K
High today
$2.39
High today$2.39
Low today
$2.04
Low today$2.04
Open price
$2.11
Open price$2.11
Volume
272.61K
Volume272.61K
52 Week high
$25.00
52 Week high$25.00
52 Week low
$1.79
52 Week low$1.79

Stock Snapshot

Moleculin Biotech(MBRX) stock is priced at $2.30, giving the company a market capitalization of 12.59M. It carries a P/E multiple of -0.07.

As of 2026-05-19, Moleculin Biotech(MBRX) stock has fluctuated between $2.04 and $2.39. The current price stands at $2.30, placing the stock +12.9% above today's low and -3.6% off the high.

Moleculin Biotech(MBRX) shares are trading with a volume of 272.61K, against a daily average of 290.27K.

During the past year, Moleculin Biotech(MBRX) stock moved between $1.79 at its lowest and $25.00 at its peak.

During the past year, Moleculin Biotech(MBRX) stock moved between $1.79 at its lowest and $25.00 at its peak.

MBRX News

Benzinga 6d
Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding

• Moleculin Biotech shares are retreating from recent levels. What’s behind MBRX decline? The MIRACLE study is comparing two dosing arms of Annamycin plus cytar...

Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding
TipRanks 6d
Moleculin Biotech expects first unblinding of MIRACLE trial data by June 30

Moleculin Biotech (MBRX) announced it is approaching the first unblinding of data from its pivotal Phase 2B/3 “MIRACLE” trial evaluating Annamycin in combinatio...

TipRanks 7d
Moleculin Nears First Unblinding in Pivotal MIRACLE Trial

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

More MBRX News

Investing.com 7d
Moleculin reports preliminary data from AML trial ahead of unblinding - Investing.com

...

Moleculin reports preliminary data from AML trial ahead of unblinding - Investing.com

People also own

Based on the portfolios of people who own MBRX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.